[1]
|
Ogita, M., Miyauchi, K., Miyazaki, T., et al. (2014) Low High-Density Lipoprotein Cholesterol Is a Residual Risk Factor Associated with Long-Term Clinical Outcomes in Diabetic Patients with Stable Coronary Artery Disease Who Achieve Optimal Control of Low-Density Lipoprotein Cholesterol. Heart and Vessels, 29, 35-41. https://doi.org/10.1007/s00380-013-0330-5
|
[2]
|
Kopin, L. and Lowenstein, C.J. (2017) Dyslipidemia. Annals of Internal Medicine, 167, 81-96. https://doi.org/10.7326/AITC201712050
|
[3]
|
Cases, A. and Coll, E. (2005) Dyslipidemia and the Progression of Renal Disease in Chronic Renal Failure Patients. Kidney International, 68, 87-93. https://doi.org/10.1111/j.1523-1755.2005.09916.x
|
[4]
|
Ballard-Hernandez, J. and Sall, J. (2023) Dyslipidemia Update. The Nursing Clinics of North America, 58, 295-308. https://Doi.Org/10.1016/J.Cnur.2023.05.002
|
[5]
|
Wang, L., Li, Y., Liu, Y., Zhang, H., Qiao, T., Chu, L., Luo, T., Zhang, Z. and Dai, J. (2023) Association between Different Types of Plant-Based Diets and Dyslipidemia in Middle-Aged and Elderly Chinese Participants. Nutrients, 15, Article 230. https://doi.org/10.3390/nu15010230
|
[6]
|
Farnier, M., Chen, E., Johnson-Levonas, A.O., et al. (2014) Effects of Extended-Release Niacin/Laropiprant, Simvastatin, and the Combination on Correlations between Apolipoprotein B, LDL Cholesterol, and Non-HDL Cholesterol in Patients with Dyslipidemia. Vascular Health and Risk Management, 10, 279-290. https://doi.org/10.2147/VHRM.S58694
|
[7]
|
Yadav, R., Liu, Y., Kwok, S., Hama, S., et al. (2015) Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients. Journal of the American Heart Association, 4, e001508. https://doi.org/10.1161/JAHA.114.001508
|
[8]
|
Teramoto, T., Abe, K. and Taneyama, T. (2013) Safety and Efficacy of Long-Term Combination Therapy with Bezafibrate and Ezetimibe in Patients with Dyslipidemia in the Prospective, Observational J-COMPATIBLE Study. Cardiovascular Diabetology, 12, Article No. 163. https://doi.org/10.1186/1475-2840-12-163
|
[9]
|
Tenenbaum, A. and Fisman, E.Z. (2012) Fibrates Are an Essential Part of Modern Anti-Dyslipidemic Arsenal: Spotlight on Atherogenic Dyslipidemia and Residual Risk Reduction. Cardiovascular Diabetology, 11, Article No. 125. https://doi.org/10.1186/1475-2840-11-125
|
[10]
|
Handelsman, Y., Jellinger, P.S., Guerin, C.K., et al. (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm. Endocrine Practice, 26, 1196-1224. https://doi.org/10.4158/CS-2020-0490
|
[11]
|
Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., et al. (2017) American Association of Clinical Endocrinologist and American College of Endocrinology Guidelines for Management of Sylipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 23, 1-87. https://doi.org/10.4158/EP171764.APPGL
|
[12]
|
Scott, M., Grundy, M.D., Neil, J.S., et al. (2019) Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1178-e1181. https://doi.org/10.1161/CIR.0000000000000699
|
[13]
|
Maron, D.J., Fazio, S. and Linton, M.F. (2000) Current Perspectives on Statins. Circulation, 101, 207-213. https://doi.org/10.1161/01.CIR.101.2.207
|
[14]
|
Istvan, E.S. and Deisenhofer, J. (2001) Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. Science, 292, 1160-1164. https://doi.org/10.1126/science.1059344
|
[15]
|
Camelia, S. and Anca, S. (2001) Statins: Mechanism of Action and Effects. Journal of Cellular and Molecular Medicine, 5, 378-387. https://doi.org/10.1111/j.1582-4934.2001.tb00172.x
|
[16]
|
Hirota, T., Fujita, Y. and Ieiri, I. (2020) An Updated Review of Pharmacokinetic Drug Interactions and Pharmacogenetics of Statins. Expert Opinion on Drug Metabolism & Toxicology, 16, 809-822 https://doi.org/10.1080/17425255.2020.1801634
|
[17]
|
Mukai, Y., Shimokawa, H., Matoba, T., et al. (2003) Acute Vasodilator Effects of HMG-CoA Reductase Inhibitors: Involvement of PI3-Kinase/Akt Pathway and Kv Channels. Journal of Cardiovascular Pharmacology, 42, 118-123. https://doi.org/10.1097/00005344-200307000-00018
|
[18]
|
Shepherd, J. (1993) Mechanism of Action of Fibrates. Postgraduate Medical Journal, 69, S34-S41.
|
[19]
|
Goa, K.L., Barradell, L.B. and Plosker, G.L. (1996) Bezafibrate: An Update of Its Pharmacology and Use in the Management of Dyslipidaemia. Drugs, 52, 725-753. https://doi.org/10.2165/00003495-199652050-00008
|
[20]
|
Packard, C.J. (1998) Overview of Fenofibrate. European Heart Journal, 19, A62-A65.
|
[21]
|
Dreyer, C., Krey, G., Keller, H., et al. (1992) Control of the Peroxisomal β-Oxidation Pathway by a Novel Family of Nuclear Hormone Receptors. Cell, 68, 879-887. https://doi.org/10.1016/0092-8674(92)90031-7
|
[22]
|
Rigano, D., Sirignano, C. and Taglialatela-Scafati, O. (2017) The Potential of Natural Products for Targeting PPARα. Acta Pharmaceutica Sinica B, 7, 427-438. https://doi.org/10.1016/j.apsb.2017.05.005
|
[23]
|
Friedenstein, A.J., Chailakhjan, R.K. and Lalykina, K.S. (1970) The Development of Fibroblast Colonies in Monolayer Cultures of Guinea-Pig Bone Marrow and Spleen Cells. Cell Proliferation, 3, 393-403. https://doi.org/10.1111/j.1365-2184.1970.tb00347.x
|
[24]
|
Pittenger, M.F., Mackay, A.M., Beck, S.C., et al. (1999) Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science, 284, 143-147. https://doi.org/10.1126/science.284.5411.143
|
[25]
|
Shilo, B.-Z. and Sprinzak, D. (2017) The Lipid-Binding Side of Notch Ligands. The EMBO Journal, 36, 2182-2183. https://doi.org/10.15252/embj.201797621
|
[26]
|
Guo, Z. and Ohlstein, B. (2015) Stem Cell Regulation. Bidirectional Notch Signaling Regulates Drosophila Intestinal Stem Cell Multipotency. Science, 350, Article aab0988. https://doi.org/10.1126/science.aab0988
|
[27]
|
Tikhonova, A.N., Dolgalev, I., Hu, H., et al. (2019) The Bone Marrow Microenvironment at Single-Cell Resolution. Nature, 569, 222-228. https://doi.org/10.1038/s41586-019-1104-8
|
[28]
|
Shen, G., Ren, H., Shang, Q., et al. (2020) Foxf1 Knockdown Promotes BMSC Osteogenesis in Part by Activating the Wnt/β-Catenin Signalling Pathway and Prevents Ovariectomy-Induced Bone Loss. eBioMedicine, 52, Article 102626. https://doi.org/10.1016/j.ebiom.2020.102626
|
[29]
|
The Prospective Epidemiological Risk Factors Study Group, Bagger, Y.Z., TankÓ, L.B., Alexandersen, P., et al. (2006) Radiographic Measure of Aorta Calcification Is a Site-Specific Predictor of Bone Loss and Fracture Risk at the Hip. Journal of Internal Medicine, 259, 598-605. https://doi.org/10.1111/j.1365-2796.2006.01640.x
|
[30]
|
Yao, W., Cheng, Z., Busse, C., et al. (2008) Glucocorticoid Excess in Mice Results in Early Activation of Osteoclastogenesis and Adipogenesis and Prolonged Suppression of Osteogenesis: A Longitudinal Study of Gene Expression in Bone Tissue from Glucocorticoid-Treated Mice. Arthritis and Rheumatism, 58, 1674-1686. https://doi.org/10.1002/art.23454
|
[31]
|
Zhao, L.-J., Liu, Y.-J., Liu, P.-Y., et al. (2007) Relationship of Obesity with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 92, 1640-1646. https://doi.org/10.1210/jc.2006-0572
|
[32]
|
Parhami, F., Tintut, Y., Beamer, W.G., et al. (2001) Atherogenic High-Fat Diet Reduces Bone Mineralization in Mice. Journal of Bone and Mineral Research, 16, 182-188. https://doi.org/10.1359/jbmr.2001.16.1.182
|
[33]
|
Pagnotti, G.M., Styner, M., Uzer, G., et al. (2019) Combating Osteoporosis and Obesity with Exercise: Leveraging Cell Mechanosensitivity. Nature Reviews Endocrinology, 15, 339-355. https://doi.org/10.1038/s41574-019-0170-1
|
[34]
|
Feldman, S., Capozza, R.F., Mortarino, P.A., et al. (2012) Site and Sex Effects on Tibia Structure in Distance Runners and Untrained People. Medicine & Science in Sports & Exercise, 44, 1580-1588. https://doi.org/10.1249/MSS.0b013e31824e10b6
|
[35]
|
Capozza, R.F., Rittweger, J., Reina, P.S., et al. (2013) PQCT-Assessed Relationships Between Diaphyseal Design and Cortical Bone Mass and Density in the Tibiae of Healthy Sedentary and Trained Men and Women. Journal of Musculoskeletal & Neuronal Interactions, 13, 195-205.
|
[36]
|
Kan, B., Zhao, Q., Wang, L., et al. (2021) Association between Lipid Biomarkers and Osteoporosis: A Cross-Sectional Study. BMC Musculoskeletal Disorders, 22, Article No. 759. https://doi.org/10.1186/s12891-021-04643-5
|
[37]
|
Cointry, G.R., Capozza, R.F., Feldman, S., et al. (2012) Estructura, Funciones Y Calidad ÓSeas. In: Ardila, E., Mautalen, C. and JimÉNez, C., Eds., Osteoporosis En IberoamÉRica, 2nd Edition, El Manual Moderno, Bogotá, 33-71.
|
[38]
|
OdÉN, A., McCloskey, E.V., Kanis, J.A., et al. (2015) Burden of High Fracture Probability Worldwide: Secular Increases 2010-2040. Osteoporosis International, 26, 2243-2248. https://doi.org/10.1007/s00198-015-3154-6
|
[39]
|
Camal Ruggieri, I.N., CÍCero, A.M., Issa, J.P.M., et al. (2021) Bone Fracture Healing: Perspectives according to Molecular Basis. Journal of Bone and Mineral Metabolism, 39, 311-331. https://doi.org/10.1007/s00774-020-01168-0
|
[40]
|
Mundy, G., Garrett, R., Harris, S., et al. (1999) Stimulation of Bone Formation in vitro and in Rodents by Statins. Science, 286, 1946-1949. https://doi.org/10.1126/science.286.5446.1946
|
[41]
|
Reid, I.R., Hague, W., Emberson, J., et al. (2001) Effect of Pravastatin on Frequency of Fracture in the LIPID Study: Secondary Analysis of a Randomised Controlled Trial. Long-Term Intervention with Pravastatin in Ischaemic Disease. The Lancet, 357, 509-512. https://doi.org/10.1016/S0140-6736(00)04042-3
|
[42]
|
Maeda, T., Kawane, T. and Horiuchi, N. (2003) Statins Augment Vascular Endothelial Growth Factor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation. Endocrinology, 144, 681-692. https://doi.org/10.1210/en.2002-220682
|
[43]
|
Oxlund, H., Dalstra, M. and Andreassen, T.T. (2001) Statin Given Perorally to Adult Rats Increases Cancellous Bone Mass and Compressive Strength. Calcified Tissue International, 69, 299-304. https://doi.org/10.1007/s00223-001-2027-5
|
[44]
|
Oxlund, H. and Andreassen, T.T. (2004) Simvastatin Treatment Partially Prevents Ovariectomy-Induced Bone Loss While Increasing Cortical Bone Formation. Bone, 34, 609-618. https://doi.org/10.1016/j.bone.2003.12.014
|
[45]
|
Bone, H.G., Kiel, D.P., Lindsay, R.S., et al. (2007) Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial. The Journal of Clinical Endocrinology & Metabolism, 92, 4671-4677. https://doi.org/10.1210/jc.2006-1909
|
[46]
|
Nezasa, K., Higaki, K., Takeuchi, M., et al. (2003) Uptake of Rosuvastatin by Isolated Rat Hepatocytes: Comparison with Pravastatin. Xenobiotica, 33, 379-388. https://doi.org/10.1080/0049825031000066259
|
[47]
|
Hughes, A., Rogers, M.J., Idris, A.I., et al. (2007) A Comparison Between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function in vitro and Ovariectomy-Induced Bone Loss in vivo. Calcified Tissue International, 81, 403-413. https://doi.org/10.1007/s00223-007-9078-1
|
[48]
|
Coxon, F.P., Helfrich, M.H., Van’t Hof, R., et al. (2000) Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298. Journal of Bone and Mineral Research, 15, 1467-1476. https://doi.org/10.1359/jbmr.2000.15.8.1467
|
[49]
|
Laing, A.J., Dillon, J.P., Mulhall, K.J., et al. (2008) Statins Attenuate Polymethylmethacrylate-Mediated Monocyte Activation. Acta Orthopaedica, 79, 134-140. https://doi.org/10.1080/17453670710014888
|
[50]
|
Chuengsamarn, S., Rattanamongkoulgul, S., Suwanwalaikorn, S., et al. (2010) Effects of Statins vs. Non-Statin Lipid-Lowering Therapy on Bone Formation and Bone Mineral Density Biomarkers in Patients with Hyperlipidemia. Bone, 46, 1011-1015. https://doi.org/10.1016/j.bone.2009.12.023
|
[51]
|
Chen, P.-Y., Sun, J.-S., Tsuang, Y.-H., et al. (2010) Simvastatin Promotes Osteoblast Viability and Differentiation via Ras/Smad/Erk/BMP-2 Signaling Pathway. Nutrition Research, 30, 191-199. https://doi.org/10.1016/j.nutres.2010.03.004
|
[52]
|
Monjo, M., Rubert, M., Ellingsen, J.E., et al. (2010) Rosuvastatin Promotes Osteoblast Differentiation and Regulates SLCO1A1 Transporter Gene Expression in MC3T3-E1 Cells. Cellular Physiology and Biochemistry, 26, 647-656. https://doi.org/10.1159/000322332
|
[53]
|
Tsubaki, M., Satou, T., Itoh, T., et al. (2012) Bisphosphonate-and Statin-Induced Enhancement of OPG Expression and Inhibition of CD9, M-CSF, and RANKL Expressions via Inhibition of the Ras/MEK/ERK Pathway and Activation of P38MAPK in Mouse Bone Marrow Stromal Cell Line ST2. Molecular and Cellular Endocrinology, 361, 219-231. https://doi.org/10.1016/j.mce.2012.05.002
|
[54]
|
Boyce, B.F. and Xing, L. (2007) Biology of RANK, RANKL, and Osteoprotegerin. Arthritis Research & Therapy, 9, Article No. S1. https://doi.org/10.1186/ar2165
|
[55]
|
Lazzerini, P.E., Capperucci, C., Spreafico, A., et al. (2013) Rosuvastatin Inhibits Spontaneous and IL-1β-Induced Interleukin-6 Production from Human Cultured Osteoblastic Cells. Joint Bone Spine, 80, 195-200. https://doi.org/10.1016/j.jbspin.2012.07.007
|
[56]
|
Li, X., Wu, F., Zhang, Y., et al. (2016) Discontinuation of Simvastatin Leads to a Rebound Phenomenon and Results in Immediate Peri-Implant Bone Loss. Clinical and Experimental Dental Research, 2, 65-72. https://doi.org/10.1002/cre2.23
|
[57]
|
Zhou, H., Xie, Y., Baloch, Z., et al. (2017) The Effect of Atorvastatin, 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor (HMG-CoA), on the Prevention of Osteoporosis in Ovariectomized Rabbits. Journal of Bone and Mineral Metabolism, 35, 245-254. https://doi.org/10.1007/s00774-016-0750-2
|
[58]
|
Kırzıoğlu, F.Y., TözÜM Bulut, M., Doğan, B., et al. (2017) Anti-Inflammatory Effect of Rosuvastatin Decreases Alveolar Bone Loss in Experimental Periodontitis. Journal of Oral Science, 59, 247-255. https://doi.org/10.2334/josnusd.16-0398
|
[59]
|
Pradeep, A.R., Garg, V., Kanoriya, D., et al. (2016) 1.2% Rosuvastatin Versus 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Placebo-Controlled Clinical Trial. Journal of Periodontology, 87, 756-762. https://doi.org/10.1902/jop.2016.150706
|
[60]
|
Pradeep, A.R., Karvekar, S., Nagpal, K., et al. (2016) Rosuvastatin 1.2 Mg in situ Gel Combined with 1:1 Mixture of Autologous Platelet-Rich Fibrin and Porous Hydroxyapatite Bone Graft in Surgical Treatment of Mandibular Class II Furcation Defects: A Randomized Clinical Control Trial. Journal of Periodontology, 87, 5-13. https://doi.org/10.1902/jop.2015.150131
|
[61]
|
Feng, X., Wang, C., Gu, Z., et al. (2019) Rosuvastatin Regulates Odontoblast Differentiation by Suppressing NF-κB Activation in an Inflammatory Environment. Cellular Reprogramming, 21, 18-25. https://doi.org/10.1089/cell.2018.0031
|
[62]
|
Leutner, M., Matzhold, C., Bellach, L., et al. (2019) Diagnosis of Osteoporosis in Statin-Treated Patients Is Dose-Dependent. Annals of the Rheumatic Diseases, 78, 1706-1711. https://doi.org/10.1136/annrheumdis-2019-215714
|
[63]
|
Hong, W., Wei, Z., Qiu, Z., et al. (2020) Atorvastatin Promotes Bone Formation in Aged ApoE-/- Mice through the Sirt1-Runx2 Axis. Journal of Orthopaedic Surgery and Research, 15, Article No. 303. https://doi.org/10.1186/s13018-020-01841-0
|
[64]
|
CÍCero, A.M., Issa, J.P.M. and Feldman, S. (2017) Matrices De Tercera GeneraciÓN En La IngenierÍA De Tejidos ÓSeos. Actualizaciones en Osteologìa, 13, Article 157.
|
[65]
|
Akbari, V., Rezazadeh, M. and Ebrahimi, Z. (2020) Comparison the Effects of Chitosan and Hyaluronic Acid-Based Thermally Sensitive Hydrogels Containing Rosuvastatin on Human Osteoblast-Like MG-63 Cells. Research in Pharmaceutical Sciences, 15, 97-106. https://doi.org/10.4103/1735-5362.278719
|
[66]
|
Özer, T., Aktaş, A., Avağ, C., et al. (2021) Evaluation of the Effects of Locally Applied Rosuvastatin on Bone Formation in a Three-Dimensional Reconstruction Rabbit Xenograft Model. Turkish Journal of Medical Sciences, 51, 3115-3125. https://doi.org/10.3906/sag-2011-109
|
[67]
|
Gautam, K., Kapoor, A., Mathur, S., et al. (2022) Comparative Evaluation of Autogenous Bone Graft and Autologous Platelet-Rich Fibrin with and without 1.2 Mg in situ Rosuvastatin Gel in the Surgical Treatment of Intrabony Defect in Chronic Periodontitis Patients. Contemporary Clinical Dentistry, 13, 69-77. https://doi.org/10.4103/ccd.ccd_740_20
|
[68]
|
Wang, Z., Li, Y., Zhou, F., et al. (2016) Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine, 95, e3042. https://doi.org/10.1097/MD.0000000000003042
|
[69]
|
Bahrami-Hessari, B. and Jansson, L. (2022) Peri-Implant Marginal Bone Loss and Systemic Statin Use: A Retrospective Cohort Pilot Study. Clinical and Experimental Dental Research, 8, 20-27. https://doi.org/10.1002/cre2.509
|
[70]
|
Leutner, M., Butylina, M., Matzhold, C., et al. (2023) Simvastatin Therapy in Higher Dosages Deteriorates Bone Quality: Consistent Evidence from Population-Wide Patient Data and Interventional Mouse Studies. Biomedicine & Pharmacotherapy, 158, Article 114089. https://doi.org/10.1016/j.biopha.2022.114089
|
[71]
|
Sharma, P., Singh, A. and Mallapragada, S. (2023) Sub-Gingival Delivery of Simvastatin and Rosuvastatin for Treatment of Chronic Periodontitis with Diabetes Mellitus: A Randomized Controlled Clinical-Radiographic Pilot Study. Journal of Oral Biology and Craniofacial Research, 13, 315-320. https://doi.org/10.1016/j.jobcr.2023.02.012
|
[72]
|
Deepanjali, M., Prasad, T.S. and Manodh, P. (2023) Efficacy of Simvastatin in Bone Regeneration after Surgical Removal of Mandibular Third Molars. Oral and Maxillofacial Surgery, 27, 427-432. https://doi.org/10.1007/s10006-022-01081-y
|
[73]
|
Still, K., Grabowski, P., Mackie, I., et al. (2008) The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation in vivo. Calcified Tissue International, 83, 285-292. https://doi.org/10.1007/s00223-008-9175-9
|
[74]
|
Syversen, U., Stunes, A.K., Gustafsson, B.I., et al. (2009) Different Skeletal Effects of the Peroxisome Proliferator Activated Receptor (PPAR)α Agonist Fenofibrate and the PPAγ Agonist Pioglitazone. BMC Endocrine Disorders, 9, Article No. 10. https://doi.org/10.1186/1472-6823-9-10
|
[75]
|
Zhong, X., Xiu, L., Wei, G., et al. (2011) Bezafibrate Prevents Palmitate-Induced Apoptosis in Osteoblastic MC3T3-E1 Cells through the NF-κB Signaling Pathway. International Journal of Molecular Medicine, 28, 535-542.
|
[76]
|
Zhong, X., Xiu, L.L., Wei, G.H., et al. (2011) Bezafibrate Enhances Proliferation and Differentiation of Osteoblastic MC3T3-E1 Cells via AMPK and ENOS Activation. Acta Pharmacologica Sinica, 32, 591-600. https://doi.org/10.1038/aps.2011.15
|
[77]
|
Stunes, A.K., Westbroek, I., Gustafsson, B.I., et al. (2011) The Peroxisome Proliferator-Activated Receptor (PPAR) Alpha Agonist Fenofibrate Maintains Bone Mass, While the PPAR Gamma Agonist Pioglitazone Exaggerates Bone Loss, in Ovariectomized Rats. BMC Endocrine Disorders, 11, Article No. 11. https://doi.org/10.1186/1472-6823-11-11
|
[78]
|
Samadfam, R., Awori, M., BÉNardeau, A., et al. (2012) Combination Treatment with Pioglitazone and Fenofibrate Attenuates Pioglitazone-Mediated Acceleration of Bone Loss in Ovariectomized Rats. Journal of Endocrinology, 212, 179-186. https://doi.org/10.1530/JOE-11-0356
|
[79]
|
Smith, S.Y., Samadfam, R., Chouinard, L., et al. (2015) Effects of Pioglitazone and Fenofibrate Co-Administration on Bone Biomechanics and Histomorphometry in Ovariectomized Rats. Journal of Bone and Mineral Metabolism, 33, 625-641. https://doi.org/10.1007/s00774-014-0632-4
|
[80]
|
Şipoş, R.S., Fechete, R., Chelcea, R.I., et al. (2015) Ovariectomized Rats’ Femur Treated with Fibrates and Statins. Assessment of Pore-Size Distribution by ¹H-NMR Relaxometry. Romanian Journal of Morphology and Embryology, 56, 743-752.
|
[81]
|
Mosti, M.P., Ericsson, M., Erben, R.G., et al. (2016) The PPARα Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats. Endocrinology, 157, 3924-3934.
|
[82]
|
Shi, T., Lu, K., Shen, S., et al. (2017) Fenofibrate Decreases the Bone Quality by Down Regulating Runx2 in High-Fat-Diet Induced Type 2 Diabetes Mellitus Mouse Model. Lipids in Health and Disease, 16, Article 201. https://doi.org/10.1210/en.2016-1114
|
[83]
|
Rovin, B.H., Barratt, J., Heerspink, H.J.L., et al. (2023) Efficacy and Safety of Sparsentan versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results from a Randomised, Active-Controlled, Phase 3 Trial. The Lancet, 402, 2077-2090. https://doi.org/10.1186/s12944-017-0592-5
|
[84]
|
Kim, Y.H., Jang, W.G., Oh, S.H., Kim, J.W., Lee, M.N., Song, J.H., et al. (2019) Fenofibrate Induces PPARα and BMP2 Expression to Stimulate Osteoblast Differentiation. Biochemical and Biophysical Research Communications, 520, 459-465. https://doi.org/10.1016/j.bbrc.2019.10.048
|
[85]
|
Thijssen, J.H. (2003) Overview on the Effects of Progestins on Bone. Maturitas, 46, 77-87. https://doi.org/10.1016/j.maturitas.2003.09.022
|
[86]
|
Alone, U.S. (2018) The Effects of Diuretics on Mineral and Bone Metabolism. Pediatric Endocrinology Reviews: PER, 15, 291-297.
|
[87]
|
Vestergaard, P. (2020) Drugs Causing Bone Loss. In: Stern, P.H., Ed., Bone Regulators and Osteoporosis Therapy, Vol. 262, Springer, Cham, 475-497. https://doi.org/10.1007/164_2019_340
|